Candid Therapeutics secures $370M to advance pioneering autoimmune therapies... and more - Life Science Headlines September 12, 2024

Candid Therapeutics secures $370M to advance pioneering autoimmune therapies with repositioned T-cell engagers San Diego, CA, September 9, 2024 (Business Wire) -- Candid Therapeutics has raised $370 million to advance novel therapies for autoimmune diseases, repurposing two T-cell engager antibodies. 

Avania appoints Jason Monteleone as CEO to drive growth and innovation in global MedTech leadership Boston, MA, September 4, 2024 (Business Wire) -- Avania has appointed Jason Monteleone as its new president and CEO, effective September 2024. 

Genetic Leap and Eli Lilly Ink $409M AI-driven deal to revolutionize RNA-based therapies New York, September 5, 2024 (PRNewswire) -- Genetic Leap and Eli Lilly have teamed up to advance genetic medicine using AI-powered RNA-targeting technology. 

Coya Therapeutics promotes Arun Swaminathan to CEO Houston, TX, August 19, 2024 (Business Wire) -- Coya Therapeutics has announced the promotion of Arun Swaminathan, Ph.D., to Chief Executive Officer, with the effective date of November 1, 2024. 

ArsenalBio Secures $325M in Oversubscribed Series C Round San Francisco, CA, September 4, 2024 (Business Wire) -- Arsenal Biosciences, a clinical-stage company focused on developing advanced CAR T-cell therapies for solid tumors, has raised $325 million in an oversubscribed Series C financing round. 

About the Author: Cari Kraft is the CEO of Jacobs Management Group, an Advisory Board Member at Experts OnTap, and the Publisher of Healthcare Sales and Marketing Magazine. Cari and her team specialize in placing top talent with Medical Device, Biotechnology, and Pharmaceutical companies nationwide.